去纤苷（defiteli）价格多少？

On October 22, 2013, defibrotide (defiteli) was approved by the European Union as the first treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation. On March 30, 2016, the U.S. Food and Drug Administration (FDA) approved defibrotide (defiteli) for the treatment of hepatic veno-occlusive disease (VOD) secondary to hematopoietic stem cell transplantation in adults and children with renal and pulmonary dysfunction. Defibrotide (defiteli) is the first and only drug to treat severe hepatic veno-occlusive disease, a rare and life-threatening disease!  

HSCT is a procedure used by some patients to treat certain cancers of the blood or bone marrow. Before the HSCT procedure, patients generally receive chemotherapy. Hepatic VOD can occur in patients receiving chemotherapy and HSCT. Hepatic VOD is a condition in which some blood vessels in the liver are blocked, causing edema and reduced blood flow in the liver. This condition can lead to the most severe liver damage. In the most severe form of hepatic VOD, patients may develop kidney and lung failure. Less than 2% of patients will develop severe hepatic VOD after HSCT, but up to 80% of patients with severe hepatic VOD will not survive. Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide (defiteli) is a single-stranded oligonucleotide mixture that has anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide (defiteli) is a safe and effective drug for preventing and treating HVOD after HSCT. 

In terms of price, the overseas price of defibrotide (defiteli sodium, defiteli) is equivalent to RMB 22,000 per box. At present, defibrotide (defiteli) is not on the market in China. If domestic patients need medication, they can obtain genuine defibrotide (defiteli) through domestic professional overseas medical service organizations (such as Medical Companion Travel).